Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

A leading pharmaceutical powerhouse renowned for innovative skincare solutions has unveiled its latest breakthrough in tackling facial hyperpigmentation. The groundbreaking serum, featuring a first-of-its-kind dual liposomal technology in India, promises enhanced skin penetration and superior results through its advanced formulation of carefully selected active ingredients.

Share Price Movement

The share price of  Alkem Laboratories Limited went up 1.7 percent to Rs. 5,193.85 per share on Wednesday, an increase from its previous close of Rs. 5,105.90 per share. The market capitalisation now stands at approximately Rs. 61,268 crore as of February 05, 2025.

What Happened

Alkem introduces Kojiglo serum in India, featuring Duo-Lipo technology for enhanced skin penetration. It combines liposomal azelaic acid, 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide to effectively target hyperpigmentation while minimising skin irritation. They have claimed this is suitable for all skin types.
Financial Highlights

In Q2FY25, revenue stood at Rs. 3,415 crore, showing a slight YoY decline of 0.7% from Rs. 3,440 crore in Q2FY24 but a strong QoQ growth of 12.6% from Rs. 3,032 crore in Q1FY25. Profit for Q2FY25 was Rs. 702 crore, reflecting a 14.1% YoY increase from Rs. 615 crore in Q2FY24 and a 27.6% QoQ rise from Rs. 550 crore in Q1FY25. Q3 results are expected on 7 February 2025.

Competitors

Alkem Laboratories competes with major pharmaceutical players like Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Dr. Reddy’s Laboratories, Lupin, Aurobindo Pharma, and Zydus Cadila in the highly competitive pharmaceutical industry.

Alkem Laboratories is currently trading at a P/E of 28.25, which is above the industry P/E of 23.82.

Market Outlook

India’s pharmaceutical industry is growing rapidly, driven by cost efficiency, strong economic factors, and policy support. With affordable treatments and advanced technology, India is a global medical hub.

The sector is expected to reach $130 billion by 2030, supported by government schemes like PLI and SPI. Increasing FDI and a strong global presence further strengthen India’s position as the ‘Pharmacy of the World. Rising investments, exports, and manufacturing capabilities ensure continued growth and global competitiveness in the coming years.

  • Related Posts

    • Pharma
    • July 14, 2025
    • 113 views
    Enrolment in third phase clinical trials for India’s first dengue vaccine nearly complete, says ICMR

    Following an announcement by the Indian Council of Medical Research (ICMR) and Panacea Biotec Limited to initiate third phase trials, about 8,000 of the targeted 10,000 participants have enrolled in…

    • Pharma
    • July 14, 2025
    • 112 views
    In Gurgaon, illegal hospital busted, quack arrested in raid

    Gurgaon: A team from the chief minister’s flying squad conducted a raid at a private hospital in Fazalwas village on Tuesday. According to police, Shivansh Hospital, located on the Tauru…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Enrolment in third phase clinical trials for India’s first dengue vaccine nearly complete, says ICMR

    Enrolment in third phase clinical trials for India’s first dengue vaccine nearly complete, says ICMR

    In Gurgaon, illegal hospital busted, quack arrested in raid

    In Gurgaon, illegal hospital busted, quack arrested in raid

    Customs delivers 25 containers of seized drugs to NAFDAC

    Customs delivers 25 containers of seized drugs to NAFDAC

    License Of Four Pharma Firms Cancelled For Illegal Drug Trade In Jammu & Kashmir

    License Of Four Pharma Firms Cancelled For Illegal Drug Trade In Jammu & Kashmir